The global In-Vitro Fertilization (IVF) market size was valued to be over USD 9.6 billion in 2014 and is expected to grow at a CAGR of over 11.7% over the next seven years. The factors that contribute to the market growth are increasing cases of infertility, the emerging trend of starting families at a later age, and advanced technologies such as lens less imaging of the sperms.
According to the American Society for Reproductive Medicine (ASRM), the inability to have a child affects around 6.7 million women in the U.S, which accounts for around 11% of the reproductive population. Moreover, 25% of the couples have more than one factors leading to infertility. In most of the cases, the male partner is either the sole cause or the contributing factor.
US In-Vitro Fertilization (IVF) market, by procedures, 2012 - 2022 (USD Million)
Intracytoplasmic Sperm Injection (ICSI) dominated the IVF market in 2014 with revenue at over USD5,400 million. ICSI has solved the shortcomings of the In-vitro fertilization treatment, where a single sperm is injected directly into the center of a fertile egg, thereby, increasing the chances of success.
ICSI along with IVF was the first ever technique in the fertility industry, which drove the demand for In-vitro fertilization. The South African Registry for ART (SARA) released its2012 report, where the data showed that out of the 6.4% of ART coverage, around 36% and 34% were for IVF and ICSI respectively.
Frozen Embryo Transfer (FET) also referred to as Frozen Embryo Replacement (FER) is the fastest growing segment owing to the similar success rate to fresh embryo transfer and other advantages such as decreased miscarriage rates, lower risk of pre-term labor, and increased implantation rates.
Moreover, in October 2013, the American Society for Reproductive Medicine (ASRM) presented its report findings on frozen embryo, which showed that women between 36 to 42 years of age had a higher live birth as compared to the fresh embryo.
Type of Cycle Insights
Fresh non-donors accounted for the largest market share in the In-vitro fertilization market in 2014. IVF with ICSI is most widely used in the case of fresh non-donor eggs or embryos followed by IVF without ICSI. According to the CDC ART trend from 2001 to 2010, the number of fresh non-donor cycles with ICSI increased to over 65%.
According to the HEFA 2012-13 report, the number of fresh In-vitro fertilization cycles has been increasing over past 10 years though the growth rate has decreased. According to the 2003-2012 trends by the CDC for the U.S., the number of fresh non-donors banking the eggs/embryos for future use has been drastically increasing.
The frozen non-donor market is the fastest growing market owing to the removal of the “experimental tag“ for frozen eggs by the American Society for Reproduction Medicines and various online portals by companies to have a better connect with the customers and providing broader service platforms.
According to the CDC 2012 data, the transfer percentage using fresh and frozen non-donors that resulted in live births or pregnancy was similar. However, the frozen method has the advantage of being less expensive, less invasive, and no requirement for fertility drug stimulation.
Culture media held the largest market share in 2014 in terms of revenue. With the increasing government funding and industrial support for employees for egg/sperm freezing, the demand for cryopreservation and the required media is expected to witness growth. The number of researches undertaken to improve the culture media is also experiencing growth.
The capital equipment segment is expected to witness rapid rise in demand as the number of patients opting for In-vitro fertilization and gamete freezing is set to increase Moreover, fertility clinics are providing a state-of-the-art equipment such as micromanipulation, non-invasive Radio Frequency Identification (RFID) tags, and others which are further expected to propel the market growth over the forecast period.
With the FDA approval of Nikon’s micromanipulation equipment, Nikon widened its microscope portfolio offering for ART. With this unique combination of manual and motorized micromanipulators, cloning was possible.
The standardization of procedures through automation, regulatory reforms and government funding for egg/sperm storage are the contributing factors for the North America In-vitro fertilization market. The government provide funds for newer experiments, which can help patients with better success rates and economical cost.
For instance, the Toronto Centre for Advanced Reproductive Technology (TCART) was the first Canadian Clinic to provide free IVF to 60 women to experiment the AUGMENT rejuvenating technique. The technique allowed older cells to rejuvenate by taking smaller cells from the outer ovary lining. This process allowed young cell harvesting and higher treatment success rate.
In 2014, Europe dominated the In-vitro fertilization market as it is the first one to come up with the In-vitro fertilization procedure, to remove the title experimental from cryopreservation of eggs, and the first one to legally approve the three parent IVF or the mitochondrial transfer technique.
Moreover, the NHS supports three cycle IVF coverage and has also spent a lot on the reproductive care research. In January 2016, fertility doctors of the UK have applied for the permission to legally use AUGMENT as an In-vitro fertilization procedure. By imbibing this procedure in the IVF treatment, older women have better chances of conceiving with the use of this egg rejuvenating technology. Human Fertilization and Embryology Authority (HFEA) has already given trial license to British fertility clinics.
Asia Pacific is the fastest growing market with a CAGR of over 13.2%.The increasing infertility issues are due to lifestyle changes leading to obesity and stress, lack of exercise, improper eating habits, lack of nutrition, and pollution accompanied with medical conditions such as diabetes.
In India, 45% of the infertility issues are not limited to women but also include male problems such as low sperm count, low sperm motility, or other morphological issues. Industrial players such as PALASH are taking up new initiatives to bring in some changes in the IVF industry. For instance, in November 2015, PALASH launched a new entity named PALASH IVF Solutions Pvt. Ltd. With this, the company has introduced a range of IVF-focused products for serving its 130+ consumers.
Competitive Market Share Insights
Key industry contributors are OvaScience, EMD SeronoInc., Vitrolife AB, Irvine Scientific, Cook Medical Inc., CooperSurgical Inc., Genea Biomedx, Thermo Fisher Scientific Inc., Genea Biomedx, Progyny, Inc., and Boston IVF.
In February 2016, Merck received European (EMA) approval for its Gonal-f prefilled pen. Gonal-f pen is an improved version of the already launched product in 2011. By taking the reviews from healthcare professionals and consumers, the company came up with a product, which was a new solution to the identified need.
The government funding to encourage egg/sperm freezing so as to bring down the chances of multiple pregnancies, technological advancement enabling pre-identification of the genetic disorder, and various industrial revolutions are expected to boom the growth market.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."